AUTHOR=Salikhov Shavkat I. , Abdurakhmonov Ibrokhim Y. , Oshchepkova Yuliya I. , Ziyavitdinov Jamolitdin F. , Berdiev Nodir Sh. , Aisa Haji Akber , Shen Jingshan , Xu Yechun , Xu H. Eric , Jiang Xiangrui , Zhang Leike , Vypova Natalia L. , Allaberganov Dilshod Sh. , Tagayalieva Nigora A. , Musabaev Erkin I. , Ibadova Gulnara A. , Rajabov Ilxom B. , Lokteva Lyubov M. 

TITLE=Repurposing of Rutan showed effective treatment for COVID-19 disease

JOURNAL=Frontiers in Medicine

VOLUME=10

YEAR=2023

URL=https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2023.1310129

DOI=10.3389/fmed.2023.1310129

ISSN=2296-858X

ABSTRACT=<p>Previously, from the tannic sumac plant (<italic>Rhus coriaria</italic>), we developed the Rutan 25 mg oral drug tablets with antiviral activity against influenza A and B viruses, adenoviruses, paramyxoviruses, herpes virus, and cytomegalovirus. Here, our re-purposing study demonstrated that Rutan at 25, 50, and 100 mg/kg provided a very effective and safe treatment for COVID-19 infection, simultaneously inhibiting two vital enzyme systems of the SARS-CoV-2 virus: 3C-like proteinase (3CLpro) and RNA-dependent RNA polymerase (RdRp). There was no drug accumulation in experimental animals’ organs and tissues. A clinical study demonstrated a statistically significant decrease in the C-reactive protein and a reduction of the viremia period. In patients receiving Rutan 25 mg (children) and 100 mg (adults), the frequency of post-COVID-19 manifestations was significantly less than in the control groups not treated with Rutan tablets. Rutan, having antiviral activity, can provide safe treatment and prevention of COVID-19 in adults and children.</p><sec><title>Clinical Trial Registration</title><p><ext-link xlink:href="https://clinicaltrials.gov/" ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink">ClinicalTrials.gov</ext-link>, ID NCT05862883.</p></sec>